Patent classifications
A61K33/02
Methods for radiotherapy to trigger light activation drugs
A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
Methods for radiotherapy to trigger light activation drugs
A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
CALCIUM BINDER FOR USE IN PREVENTING STILLBIRTH
This disclosure pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. This disclosure also pertains to compositions comprising a calcium binder, particularly in combination with a chloride salt to supplement a diet of an animal, in particular, a pregnant animal.
CALCIUM BINDER FOR USE IN PREVENTING STILLBIRTH
This disclosure pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. This disclosure also pertains to compositions comprising a calcium binder, particularly in combination with a chloride salt to supplement a diet of an animal, in particular, a pregnant animal.
Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
Metal-carbon structure hybrid formulation for dental use in the treatment of dental hypersensitivity, demineralization and cavities
The present invention relates to an antibacterial composition which, when applied to the surface of a tooth, allows remineralisation of the enamel to occur, said composition having very low toxicity for human use. When applied, the composition leaves no stains and does not alter the visible colour characteristics of the teeth to which it has been applied.
Metal-carbon structure hybrid formulation for dental use in the treatment of dental hypersensitivity, demineralization and cavities
The present invention relates to an antibacterial composition which, when applied to the surface of a tooth, allows remineralisation of the enamel to occur, said composition having very low toxicity for human use. When applied, the composition leaves no stains and does not alter the visible colour characteristics of the teeth to which it has been applied.
METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USE
Disclosed is a method of obtaining an inorganic nanostructured complex (CFI-1) by chemical synthesis and antitumor use. The main use is in treating cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.
METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USE
Disclosed is a method of obtaining a protein-associated nanostructured complex (MRB-CFI-1) by chemical synthesis and antitumor use. The main use is in treating cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.